摘要
目的:探讨幽门螺杆菌(Hp)阳性胃溃疡(GU)患者应用康复新液联合四联疗法治疗的效果。方法:采用随机数字表法将2020年5月-2022年5月于九江市第一人民医院就诊的92例Hp阳性GU患者分为两组,每组46例。对照组予以四联疗法治疗,观察组在对照组基础上加用康复新液治疗,均连续治疗2周。比较两组临床疗效、炎症因子水平、胃肠道激素水平、生活质量、Hp根除率及不良反应。结果:治疗后,观察组总有效率、生活质量评分及Hp根除率均较对照组高,肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、C反应蛋白(CRP)、胃泌素(GAS)、胃动素(MTL)水平均较对照组低,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:Hp阳性GU患者应用康复新液联合四联疗法治疗,利于减轻炎症反应,调节胃肠道激素,提高生活质量,效果显著,安全可靠。
Objective:To investigate the effect of Kangfuxin Liquid combined with quadruple therapy in patients with Helicobacter pylori(Hp)positive gastric ulcer(GU).Method:A total of 92 patients with Hp positive GU who were admitted to Jiujiang NO.1 People's Hospital from May 2020 to May 2022 were divided into two groups according to random number table method,46 cases in each group.The control group was treated with quadruple therapy,and the observation group was treated with Kangfuxin Liquid on the basis of the control group,both of which were treated for 2 weeks continuously.The clinical efficacy,inflammatory factors levels,gastrointestinal hormone levels,quality of life,Hp eradication rate and adverse reactions were compared between the two groups.Result:After treatment,the total effective rate,quality of life scores and Hp eradication rate of the observation group were higher than those of the control group,and the levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),C reactive protein(CRP),gastrin(GAS)and motilin(MTL)were lower than those of the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The application of Kangfuxin Liquid combined with quadruple therapy in patients with Hp positive GU is beneficial to reduce inflammatory reaction,regulate gastrointestinal hormone and improve quality of life,with remarkable effect,safety and reliability.
作者
黄萍
伍灵志
HUANG Ping;WU Lingzhi(Jiujiang NO.1 People's Hospital,Jiangxi Province,Jiujiang 332000,China;不详)
出处
《中国医学创新》
CAS
2023年第12期26-29,共4页
Medical Innovation of China